Board of Directors
Andy Blauvelt, M.D., MBA
Medical Board Chair
Dr. Blauvelt is an Investigator at Oregon Medical Research Center (OMRC), a small business dedicated to performing high quality clinical research studies in dermatology. He received his undergraduate degree in electrical engineering at Purdue University, his medical degree at Michigan State University, and a healthcare MBA at Oregon Health & Science University (OHSU). Dr. Blauvelt trained in dermatology at the University of Miami and in cellular immunology under the direction of Dr. Steve Katz at the National Institutes of Health (NIH). Earlier in his career, he held senior staff positions at the NIH (Senior Investigator), OHSU (Professor), and the Portland VA Medical Center (Chief) as well as being Owner and President of OMRC from 2013-2022.
Dr. Blauvelt has extensive experience in both basic and clinical research related to psoriasis. Within psoriasis immunology research, his laboratory published key papers on the role of IL-23/Th17 biology in this disease. In the clinic, he founded and ran OHSU’s Center of Excellence for Psoriasis and Psoriatic Arthritis (CEPPA), one of the first clinics in the country to be focused on multidisciplinary care of patients with psoriasis. In recent years, he has been the international lead/senior investigator on a number of important clinical trials in psoriasis, including PSTELLAR, FEATURE, CLEAR, IXORA-R, VOYAGE 1, ECLIPSE, IMMhance, BE ABLE 1, BE ABLE 2, BE READY, BE RADIANT, OASIS-1, and POETYK PSO-1.
Dr. Blauvelt has published over 350 papers and spoken across the country and world on all aspects of psoriasis. In 2021 and 2022, he made the lists of Highly Cited Researchers, representing the top 1% of cited scientists in the world. Dr. Blauvelt is also an elected member of the American Society for Clinical Investigation, the International Psoriasis Council, and the International Eczema Council. In 2023, he became Chair of the Medical Board for the National Psoriasis Foundation, an organization he has worked closely with for over 20 years in a variety of capacities.